We would love to hear your thoughts about our site and services, please take our survey here.
Good point comeK2.
The negotiation process is not as simplistic as implied. (One of the disciplines in my last life). Also, there is nothing to imply that LO did not have a side chat. Have to give the BoD credit for driving the company to this point, not a minor feat. I guess Barder's cynical body language reflected the tone of impatience in the questions and lack of appreciation of the success thus far. This project is ongoing and stuff is happening, this format does not favour the daily SP watchers. The SP fluctuations encourage (day ) traders and I have no doubt some are manipulating and making money. MM,s are not complaining, cycle of life in the finance world. This will come good, of that i have no doubt.
Not sure what more the investors were expecting at this release of results, some magic words perhaps to send the SP to lunar sphere? I guess that is why Barder stared out of the window looking totally disinterested. Wonder what is was watching out there.
Launches are property of the distributors, who will have their own pre-launch news release and duty to their own share holders.
FUM revenue is predominately dependent upon royalty payments.
It has always been about the US launch, which could come at anytime from now to early 2025.
Unlike other AIM situations, where waiting for oil discovery results, gold mining strikes or partnership deals etc.. FUM has a working, proven product awaiting to hit the sales market. There is no ambiguity regarding it's credibility.
People who are anxious about the SP are the ones waiting to sell up on any decent SP rise others are in for the dividends.
Coordinated marketing launch is what is required.
OTC sales will not be insignificant however, online sales is where it's at. I would not be surprised if Eroxon project managers from the distribution companies are not meeting regularly. Successful launch of Eroxon is in everyone concerned's interest.
Whether any news of this is tied in with the results , we'll have to see. Results on their own will not cut the mustard. IMO
Yes, My fear too, 'more of the same' in a different format.
one sure way to have improved the SP and confidence, would have been for the board to have bought in before the 'closed period'. Let's hope the PR machine has been busy in the background.
Not surprised at no open shorts. Shorts are Usually a bet on a large anticipated drop, possibly after some outcome.
I can not see any significant drop, even if early results are not as expected. Nothing will change. Eroxon will still work, however many new markets will open and demand will pickup. Current market cap only reflects the status quo. There's so much more to come.
Eroxon has been approved for OTC use by EU,UK and USA. Proven to work in over 60% of ED suffers (probably 90% for non-ED suffers) by all three. Distribution deals signed with two large and most appropriate companies. FDA and NHS endorsed it. None of this can be retracted, it's a fact. This would suggest that it is only a matter of time before there is a 'break-out'.
Two questions:
What's with the SP?
What exactly is the downside?
Answers on a postcard and send to the sellers.
...So Nickname (Liam?)
FUM tested
Europe CE accredited
Approved by FDA (Via extended study)
Approved by NICE for NHS
Due diligence by Atlantis Grp
Due diligence by Coopers
Due diligence by Haleon
Won Boots best product award
All these people got it wrong, it was a placebo effect after all, the daft people could not see it! .....And you did!
What a clever person you are.
FUM tested
Europe CE accredited
Approved by FDA (Via extended study)
Approved by NICE for NHS
Due diligence by Atlantis Grp
Due diligence by Coopers
Due diligence by Haleon
Won Boots best product award
Vs
'Suspect' Boots feedback. (Do the math!)
Even if a small percentage of the established ED success rate is converted to sale + NHS users (UK) + the recreational users (which I feel will turnout to be the largest user group, in future), this will be BIG.
Someone mentioned L/O (Largest share holder 28.5%) exit strategy. IMO Don't hold your breath. This is a growth fund now.
NICE (UK) and FDA (USA) approvals are not pie in the sky endorsements. They are fact based and are government represented authorities.
No one can entertain the idea that this does not work.
It's the real thing!
The genie is out of the bottle and it ain't going back.
At some point in time (not long now) the SP will catch up with the broker price. Unlike previous 'milestone RSN' SP reactions, the future RSN,s will have a positive push, not withstanding the F/Y numbers.
Getting better.
Beach.
your synopsis is one version, largely plausible and well articulated. One assumption made which rocks the boat for me is ."....who needed who the most - FUM of Coopers I would suggest..."
As I recall, FUM stated that they were looking at several prospective distributors, does not suggest that FUM were in "..hardly good negotiating position". I would go further and suggest that the situation was quite the contrary.
although, they may have given up 'some' ground in choosing Haleon.
Whilst the omens are looking good and all the ducks appear to be lining up nicely, the litmus test will, indeed be F/Y numbers. I suspect these are also been eagerly awaited for the city scribblers, who are sitting on cash looking for a home.....and almost certainly a catalyst for a boost in that long awaited rocket take off.
As this is not 'death' or 'taxes', which are certain, this is not....but is looking good!
This news has to be equivalent to the US FDA approval. Any launches in remaining countries can refer to these approvals as reference to the legitimacy of the product. NHS and FDA, Two of the most controlled and respected agencies endorsed/approved. They'll have to come up with more than just bad reviews to trump this news. It's official....it works!
This news is bigger than it first appears. NHS/government approved means they feel there is a real benefit for patients using Eroxon. Buys the advertisers the bragging rights. This is heading to be a household name.
Looking good!
News about numerous launches is filtering through on this bulletin board. Whilst all of this is welcomed and should help boost the SP, it should really be coming through FUM IR. House brokers also have a responsibility. Negligence or conscious decision?
2024 is likely to be dynamic, hopefully IR will be a little more proactive.
Absolutely agree Bandit.
In the 80's when management went on jollies disguised as team building exercise, I found myself on a communication builder. One such exercise was forming a circle and whispering an ambiguous message to the person to your left. By the time it did a full round the message would be totally different.
If there is not clear direction, people make up their own stories.
I see no clear messaging here, leaving the SP swaying.
No one is expecting a running commentary however, some SP affecting releases would help.